Unexpected Analyst 12-Month Forecast for SCHM
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Should l Buy GKOS?
Source: NASDAQ.COM
ETF Analysis: The Schwab U.S. Mid-Cap ETF (SCHM) has an implied analyst target price of $33.94, indicating a potential upside of 14.77% from its current trading price of $29.57.
Notable Holdings: Key underlying holdings with significant upside potential include Glaukos Corp (53.33% upside), Darling Ingredients Inc (45.94% upside), and CCC Intelligent Solutions Holdings Inc (37.81% upside) based on their respective analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets may lead to downgrades if they do not align with recent developments.
Investor Research: Investors are encouraged to conduct further research to assess the validity of analyst targets and their implications for future stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GKOS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GKOS
Wall Street analysts forecast GKOS stock price to fall
13 Analyst Rating
12 Buy
0 Hold
1 Sell
Strong Buy
Current: 135.270
Low
72.00
Averages
127.08
High
165.00
Current: 135.270
Low
72.00
Averages
127.08
High
165.00
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Glaukos Reports Record Q1 2026 Earnings and Raises Guidance
- Record Sales Performance: Glaukos reported a record net sales of $150.6 million in Q1 2026, reflecting a 41% year-over-year increase, indicating strong market performance that is likely to drive stock price appreciation.
- iDose TR Sales Surge: The U.S. glaucoma franchise achieved net sales of $93.5 million, up 58% year-over-year, with iDose TR contributing approximately $54 million, showcasing the company's success in new product adoption and enhancing competitive positioning.
- Epioxa Commercialization Progress: Epioxa, an incision-free alternative for corneal cross-linking, has been launched across areas serving about 65% of the U.S. population, with plans to expand to approximately 95%, significantly increasing market penetration and revenue potential.
- Margin Improvement: The first quarter saw an 84% gross margin, up 120 basis points from last year, with management maintaining a full-year margin guidance of 84% to 86%, indicating a positive outlook for cost control and profitability.
See More
Glaukos (GKOS) Q1 2026 Earnings Transcript
See More
Glaukos Q1 Earnings Announcement Scheduled
- Earnings Announcement Schedule: Glaukos (GKOS) is set to announce its Q1 earnings on April 29th after market close, with a consensus EPS estimate of -$0.28, reflecting a 27.3% year-over-year decline, indicating challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $137 million, representing a 28.4% year-over-year increase, showcasing strong growth potential driven by new product launches.
- Performance Estimate Revisions: Over the past three months, EPS estimates have seen two upward revisions and ten downward revisions, while revenue estimates have experienced eight upward revisions and one downward revision, indicating market uncertainty regarding the company's future performance.
- Historical Performance Review: Over the last two years, Glaukos has beaten EPS estimates 50% of the time and has achieved a 100% success rate in exceeding revenue estimates, demonstrating stability in revenue and market confidence.
See More
Glaukos Corporation Schedules Q1 2026 Earnings Call and Webcast
- Earnings Release Schedule: Glaukos Corporation plans to release its Q1 2026 financial results after market close on April 29, 2026, with management discussing the results during a conference call and webcast at 1:30 PM PT (4:30 PM ET), providing insights into the company's financial performance and future outlook.
- Participation Details: Investors can join the conference call by dialing 800-715-9871 (U.S.) or 646-307-1963 (International) and entering Conference ID 1333241, with a replay available post-call for those unable to attend live, ensuring accessibility to key financial discussions.
- Innovative Product Launch: Since launching its first Micro-Invasive Glaucoma Surgery (MIGS) device in 2012, Glaukos has continued to innovate in the treatment of glaucoma, corneal disorders, and retinal diseases, with the 2024 launch of iDose®TR offering continuous 24/7 glaucoma drug therapy, representing a significant advancement in treatment options.
- Market Positioning and Development: As the sole developer of the FDA-approved corneal cross-linking therapy, Glaukos is committed to improving treatment outcomes for keratoconus patients through its proprietary bio-activated pharmaceutical, showcasing the company's leadership in ophthalmic medical technology.
See More
Epioxa™ HD: First Incision-Free Drug Therapy for Keratoconus Approved by FDA
- Innovative Drug Launch: Glaukos announces the commercial availability of Epioxa™ HD as the first FDA-approved incision-free therapy for keratoconus, representing a significant breakthrough in treatment standards that is expected to greatly enhance patient experience and recovery times.
- Patient Support Programs: The company plans to increase investments in patient awareness, education, and access, launching multiple support initiatives including a co-pay assistance program and a patient assistance program aimed at addressing the longstanding issues of underdiagnosis and undertreatment in the keratoconus patient community.
- Significant Clinical Outcomes: Epioxa reduces pain associated with traditional epithelial removal through its enriched oxygen and light mechanism, providing a more comfortable treatment experience while ensuring clinically meaningful outcomes, delivering exceptional value to patients and the healthcare system.
- Substantial Market Potential: With the launch of Epioxa, Glaukos anticipates attracting more attention from keratoconus patients, increasing market share, and driving continued growth in the ophthalmic treatment sector through innovative technologies.
See More
Wingstop Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Wingstop reported an adjusted EPS of $1.00 for Q4, surpassing analyst expectations of $0.84, indicating strong profitability and boosting market confidence in the company's future performance.
- Sales Miss: The quarterly sales of $175.694 million fell short of the analyst consensus estimate of $177.533 million, yet the overall performance reflects the company's resilience in a competitive fast-food market.
- Stock Surge: Following the earnings report, Wingstop's shares jumped 17.3% to $295.31 on Wednesday, signaling optimistic investor sentiment and potentially attracting more institutional interest in the stock.
- Positive Market Reaction: The broader U.S. stock market rose, with the Dow Jones index gaining around 250 points on Wednesday, and Wingstop's strong performance further fueled market optimism, reflecting investor confidence in the recovery of the restaurant sector.
See More
Glaukos Reports Record Q1 2026 Earnings and Raises Guidance
- Record Sales Performance: Glaukos reported a record net sales of $150.6 million in Q1 2026, reflecting a 41% year-over-year increase, indicating strong market performance that is likely to drive stock price appreciation.
- iDose TR Sales Surge: The U.S. glaucoma franchise achieved net sales of $93.5 million, up 58% year-over-year, with iDose TR contributing approximately $54 million, showcasing the company's success in new product adoption and enhancing competitive positioning.
- Epioxa Commercialization Progress: Epioxa, an incision-free alternative for corneal cross-linking, has been launched across areas serving about 65% of the U.S. population, with plans to expand to approximately 95%, significantly increasing market penetration and revenue potential.
- Margin Improvement: The first quarter saw an 84% gross margin, up 120 basis points from last year, with management maintaining a full-year margin guidance of 84% to 86%, indicating a positive outlook for cost control and profitability.
See More
Glaukos (GKOS) Q1 2026 Earnings Transcript
See More
Glaukos Q1 Earnings Announcement Scheduled
- Earnings Announcement Schedule: Glaukos (GKOS) is set to announce its Q1 earnings on April 29th after market close, with a consensus EPS estimate of -$0.28, reflecting a 27.3% year-over-year decline, indicating challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $137 million, representing a 28.4% year-over-year increase, showcasing strong growth potential driven by new product launches.
- Performance Estimate Revisions: Over the past three months, EPS estimates have seen two upward revisions and ten downward revisions, while revenue estimates have experienced eight upward revisions and one downward revision, indicating market uncertainty regarding the company's future performance.
- Historical Performance Review: Over the last two years, Glaukos has beaten EPS estimates 50% of the time and has achieved a 100% success rate in exceeding revenue estimates, demonstrating stability in revenue and market confidence.
See More
Glaukos Corporation Schedules Q1 2026 Earnings Call and Webcast
- Earnings Release Schedule: Glaukos Corporation plans to release its Q1 2026 financial results after market close on April 29, 2026, with management discussing the results during a conference call and webcast at 1:30 PM PT (4:30 PM ET), providing insights into the company's financial performance and future outlook.
- Participation Details: Investors can join the conference call by dialing 800-715-9871 (U.S.) or 646-307-1963 (International) and entering Conference ID 1333241, with a replay available post-call for those unable to attend live, ensuring accessibility to key financial discussions.
- Innovative Product Launch: Since launching its first Micro-Invasive Glaucoma Surgery (MIGS) device in 2012, Glaukos has continued to innovate in the treatment of glaucoma, corneal disorders, and retinal diseases, with the 2024 launch of iDose®TR offering continuous 24/7 glaucoma drug therapy, representing a significant advancement in treatment options.
- Market Positioning and Development: As the sole developer of the FDA-approved corneal cross-linking therapy, Glaukos is committed to improving treatment outcomes for keratoconus patients through its proprietary bio-activated pharmaceutical, showcasing the company's leadership in ophthalmic medical technology.
See More
Epioxa™ HD: First Incision-Free Drug Therapy for Keratoconus Approved by FDA
- Innovative Drug Launch: Glaukos announces the commercial availability of Epioxa™ HD as the first FDA-approved incision-free therapy for keratoconus, representing a significant breakthrough in treatment standards that is expected to greatly enhance patient experience and recovery times.
- Patient Support Programs: The company plans to increase investments in patient awareness, education, and access, launching multiple support initiatives including a co-pay assistance program and a patient assistance program aimed at addressing the longstanding issues of underdiagnosis and undertreatment in the keratoconus patient community.
- Significant Clinical Outcomes: Epioxa reduces pain associated with traditional epithelial removal through its enriched oxygen and light mechanism, providing a more comfortable treatment experience while ensuring clinically meaningful outcomes, delivering exceptional value to patients and the healthcare system.
- Substantial Market Potential: With the launch of Epioxa, Glaukos anticipates attracting more attention from keratoconus patients, increasing market share, and driving continued growth in the ophthalmic treatment sector through innovative technologies.
See More
Wingstop Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Wingstop reported an adjusted EPS of $1.00 for Q4, surpassing analyst expectations of $0.84, indicating strong profitability and boosting market confidence in the company's future performance.
- Sales Miss: The quarterly sales of $175.694 million fell short of the analyst consensus estimate of $177.533 million, yet the overall performance reflects the company's resilience in a competitive fast-food market.
- Stock Surge: Following the earnings report, Wingstop's shares jumped 17.3% to $295.31 on Wednesday, signaling optimistic investor sentiment and potentially attracting more institutional interest in the stock.
- Positive Market Reaction: The broader U.S. stock market rose, with the Dow Jones index gaining around 250 points on Wednesday, and Wingstop's strong performance further fueled market optimism, reflecting investor confidence in the recovery of the restaurant sector.
See More
